For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > REGULATORY
REGULATORY
- Investigation of COVID-19 Jab Disposals Not on the Table at This Time: Health Minister
May 20, 2022
- LDP Pharma Study Group to Push Price Maintenance for Patented Meds, Rethink of “Off-Year” Re-Pricing towards Honebuto
May 20, 2022
- LDP Social Security Execs Leery of Macroeconomic Indexing
May 20, 2022
- Chuikyo OKs Listing of 14 Drugs on May 25, Biggest Peak Sales Forecast for Vabysmo
May 19, 2022
- Japan Govt Promulgates Economic Security Law
May 19, 2022
- Cabometyx Likely to Escape CEA Scheme Unscathed with No Price Cut
May 19, 2022
- 4 Drugs Face Zero Premium Rule for Low Cost Disclosures: May Price Listing
May 19, 2022
- Impact of Annual Price Revisions on Pharma Industry Hard to Gauge Comprehensively: Govt
May 19, 2022
- Cabinet Adopts Ordinance for Emergency Approval, COVID Drugs Subject to New System
May 18, 2022
- 2022 Honebuto Outline Calls for “Planned Investment” Towards a New Capitalism
May 18, 2022
- Dupixent Faces Second Re-Pricing in August with 11.7% Cut
May 18, 2022
- Taiho’s GIST Med Pimitespib, Cabotegravir/Rilpivirine Combo Use Up for PAFSC Review on May 30
May 18, 2022
- MHLW Panels Again Find No Significant Concerns over Safety of COVID-19 Vaccines
May 17, 2022
- Janssen’s COVID-19 Vaccine Up for MHLW Panel Review on May 30
May 17, 2022
- MHLW Orders Label Revisions for Dexamethasone, Betamethasone to Warn of Phaeochromocytoma Crisis
May 16, 2022
- 5 New Probable Cases of Acute Pediatric Hepatitis Found in Japan
May 16, 2022
- Japan Clears Bill to Create Emergency Approval System, Enforcement Slated by Month-End
May 13, 2022
- Health Minister Vows Thorough Discussions on Drug Pricing, Mentions Policy Veterans’ Proposals
May 13, 2022
- MHLW Panel Clears Solasia’s PTCL Drug for Approval
May 13, 2022
- Japan Confirms 1st Cases of BA.4, BA.5 Omicron Subvariants
May 13, 2022
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…